Posted by Michael Wonder on 25 Apr 2026
Bristol Myers Squibb and Pfizer to make Eliquis (apixaban) available via Mark Cuban Cost Plus Drug Company
24 April 2026 - Expands Options for Cash-Paying Patients to Access the Nation’s #1 Prescribed Oral Blood Thinner
The Bristol Myers Squibb-Pfizer Alliance today announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to offer Eliquis (apixaban) on CostPlusDrugs.com. Eliquis is one of the most widely prescribed oral anticoagulants in the US and one of the largest brands in the space to be offered on the site, which allows patients to purchase prescription medicines directly at reduced costs, providing another avenue for patients to access the medication.
Beginning 27 April 2026, Eliquis will be available on Cost Plus Drugs, and patients with a prescription will pay a total of $345 for a 30 day supply. Teaming up with Cost Plus Drugs provides another option for cash paying patients to access Eliquis directly. This follows the 2025 launch of a direct to patient offering through the BMS-Pfizer Alliance’s patient resource Eliquis 360 Support, which is also accessible via BMS Patient Connect.
